SMT202200377T1 - Aza-e terociclici a 6 elementi contenenti composti modulanti il recettore oppioide delta, metodi di utilizzo e produzione degli stessi - Google Patents

Aza-e terociclici a 6 elementi contenenti composti modulanti il recettore oppioide delta, metodi di utilizzo e produzione degli stessi

Info

Publication number
SMT202200377T1
SMT202200377T1 SM20220377T SMT202200377T SMT202200377T1 SM T202200377 T1 SMT202200377 T1 SM T202200377T1 SM 20220377 T SM20220377 T SM 20220377T SM T202200377 T SMT202200377 T SM T202200377T SM T202200377 T1 SMT202200377 T1 SM T202200377T1
Authority
SM
San Marino
Prior art keywords
making
methods
same
opioid receptor
modulating compounds
Prior art date
Application number
SM20220377T
Other languages
English (en)
Italian (it)
Inventor
Guodong Liu
Catherine C K Yuan
Aimee Crombie Speerschneider
Dennis Shinji Yamashita
Philip Michael Pitis
Michael John Hawkins
Daubert Tamara Ann Miskowski
Kargbo Robert Borbo
Robert Jason Herr
Donna Romero
Gregory J Pacofsky
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of SMT202200377T1 publication Critical patent/SMT202200377T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
SM20220377T 2015-09-02 2016-08-30 Aza-e terociclici a 6 elementi contenenti composti modulanti il recettore oppioide delta, metodi di utilizzo e produzione degli stessi SMT202200377T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213203P 2015-09-02 2015-09-02
EP16842832.4A EP3344248B1 (en) 2015-09-02 2016-08-30 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
PCT/US2016/049526 WO2017040545A1 (en) 2015-09-02 2016-08-30 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Publications (1)

Publication Number Publication Date
SMT202200377T1 true SMT202200377T1 (it) 2022-11-18

Family

ID=58188367

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220377T SMT202200377T1 (it) 2015-09-02 2016-08-30 Aza-e terociclici a 6 elementi contenenti composti modulanti il recettore oppioide delta, metodi di utilizzo e produzione degli stessi

Country Status (22)

Country Link
US (3) US10246436B2 (enExample)
EP (2) EP3344248B1 (enExample)
JP (2) JP6898310B2 (enExample)
KR (1) KR102787317B1 (enExample)
CN (2) CN114773318A (enExample)
AU (2) AU2016315720B2 (enExample)
CA (1) CA3015702A1 (enExample)
CY (1) CY1125225T1 (enExample)
DK (1) DK3344248T3 (enExample)
ES (1) ES2920130T3 (enExample)
HR (1) HRP20220735T1 (enExample)
HU (1) HUE058819T2 (enExample)
IL (1) IL257503B (enExample)
LT (1) LT3344248T (enExample)
MA (1) MA43313B1 (enExample)
MD (1) MD3344248T2 (enExample)
PL (1) PL3344248T3 (enExample)
PT (1) PT3344248T (enExample)
RS (1) RS63319B1 (enExample)
SI (1) SI3344248T1 (enExample)
SM (1) SMT202200377T1 (enExample)
WO (1) WO2017040545A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702408B2 (en) 2017-02-17 2023-07-18 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
AU2018221705B2 (en) 2017-02-17 2022-10-27 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法
CN113880815B (zh) * 2020-07-03 2024-03-29 中国药科大学 一类吲哚衍生物及其制备方法和用途
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形
JP2022135015A (ja) * 2021-03-04 2022-09-15 国立大学法人東京工業大学 オピオイド受容体作動剤
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (enExample) 1972-11-30 1975-04-07 Pharmacia Ab
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US5086063A (en) 1988-03-28 1992-02-04 Du Pont Merck Pharmaceutical Company 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
AU706839B2 (en) 1996-03-29 1999-06-24 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ANT)agonists of 5-HT1A- and/or 5-HT1D receptors
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
CA2683097A1 (en) * 1998-03-10 1999-09-16 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
WO2001032178A1 (en) 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CN100372850C (zh) * 2003-02-12 2008-03-05 神经研究公司 新的8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005032464A2 (en) 2003-09-30 2005-04-14 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
BRPI0513433A (pt) 2004-07-16 2008-05-06 Schering Corp derivados de hidantoìna para o tratamento de distúrbios inflamatórios
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7098203B2 (en) 2004-07-20 2006-08-29 Bristol-Myers Squibb Company Homopiperidine derivatives as NK-1 antagonists
US7872023B2 (en) 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
CA2631221C (en) 2005-12-01 2014-06-03 F. Hoffmann-La Roche Ag Serotonin transporter (sert) inhibitors
US20070142389A1 (en) 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
WO2007106469A2 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
SI2101740T1 (sl) 2006-12-04 2014-03-31 Orexo Ab Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode
US9242933B2 (en) * 2007-05-25 2016-01-26 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)
KR101167774B1 (ko) 2007-08-07 2012-07-24 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서의 피롤리딘 아릴-에터
BRPI0820632A2 (pt) 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
US8664214B2 (en) * 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6055784B2 (ja) 2012-01-31 2016-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 パロキセチン誘導体
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP2941431B1 (en) * 2012-12-28 2017-10-25 Purdue Pharma L.P. Substituted morphinans and the use thereof
EP3183232B1 (en) 2014-08-22 2023-05-03 The Arizona Board of Regents on behalf of The University of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
ES2913117T3 (es) * 2015-06-26 2022-05-31 Univ Michigan Regents Inhibidores de quinasa receptora acoplada a proteína G y métodos para el uso de los mismos

Also Published As

Publication number Publication date
US20170210725A1 (en) 2017-07-27
PL3344248T3 (pl) 2022-07-18
MD3344248T2 (ro) 2022-10-31
US10246436B2 (en) 2019-04-02
ES2920130T3 (es) 2022-08-01
JP2021138744A (ja) 2021-09-16
SI3344248T1 (sl) 2022-07-29
US20200231564A9 (en) 2020-07-23
CN108025002B (zh) 2022-05-13
EP3344248A4 (en) 2019-07-10
HRP20220735T1 (hr) 2022-09-02
IL257503A (en) 2018-04-30
PT3344248T (pt) 2022-06-29
CY1125225T1 (el) 2025-03-28
DK3344248T3 (da) 2022-06-20
US20230203002A1 (en) 2023-06-29
CN108025002A (zh) 2018-05-11
EP4086249A3 (en) 2023-02-15
EP3344248B1 (en) 2022-03-23
HK1257927A1 (en) 2019-11-01
JP6898310B2 (ja) 2021-07-07
HK1254498A1 (zh) 2019-07-19
EP3344248A1 (en) 2018-07-11
JP2018527354A (ja) 2018-09-20
KR102787317B1 (ko) 2025-03-26
CA3015702A1 (en) 2017-03-09
AU2021203337A1 (en) 2021-06-24
MA43313B1 (fr) 2022-06-30
AU2016315720A1 (en) 2018-03-15
EP4086249A2 (en) 2022-11-09
WO2017040545A1 (en) 2017-03-09
KR20180041751A (ko) 2018-04-24
LT3344248T (lt) 2022-06-27
MA43313A (fr) 2018-10-03
JP7463318B2 (ja) 2024-04-08
US11465980B2 (en) 2022-10-11
US20190202803A1 (en) 2019-07-04
AU2016315720B2 (en) 2021-02-25
IL257503B (en) 2021-10-31
RS63319B1 (sr) 2022-07-29
CN114773318A (zh) 2022-07-22
HUE058819T2 (hu) 2022-09-28
NZ739934A (en) 2024-07-05

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL285229A (en) Compounds and methods for modulating RNA function
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
IL259803A (en) Kinase Modulating Compounds and Methods and Labels Therefor
IL257989A (en) Compounds and methods for modulating the expression of angiotensinogen
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
SG11202004113VA (en) Sting modulator compounds, and methods of making and using
EP3218483A4 (en) Compounds and methods for the modulation of proteins
MY193661A (en) Anti-tim3 antibodies and methods of use
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
ZA201800601B (en) Novel breathing control modulating compounds, and methods of making and using same
IL257503B (en) Compounds containing a six-membered aza-heterocyclic ring that modulate the opioid-delta receptor, methods for their use and preparation
PL3319963T3 (pl) Podstawione 4-azaindole i ich zastosowanie jako modulatorów receptora GluN2B
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
IL268414A (en) Delta-opioid receptor modulator compounds containing pentamerized aza-heterocycles, methods for their use and preparation
PT3359556T (pt) Modulação da atividade de citocinas gama-c
ZA201602890B (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
EP3154547A4 (en) Pyrimidine compounds and methods using the same
EP3454845A4 (en) ADRENO RECEPTOR MODULATING CONNECTIONS AND METHOD FOR USE THEREOF
IL248792B (en) hsp70 modulators and methods for their preparation and use
IL268415B (en) Delta-opioid receptor modulator compounds containing 7-atom aza-heterocycles, methods for their use and preparation
SG11202101060WA (en) Bicyclic compounds as kinase modulators, methods and uses thereof
EP3129868A4 (en) Expandable application representation, milestones, and storylines
SG11201609348PA (en) Biological adhesives and sealants and methods of using the same